CLBS Caladrius Biosciences Inc.

2.6
+0.02  (+1%)
Previous Close 2.58
Open 2.55
Price To Book 0.78
Market Cap 27,039,818
Shares 10,399,930
Volume 7,033
Short Ratio
Av. Daily Volume 26,626
Stock charts supplied by TradingView

NewsSee all news

  1. Caladrius Biosciences to Participate at Upcoming December Conferences

    BASKING RIDGE, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

  2. Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019

    Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events CLBS16 cell therapy shows promise as a significant advancement in treatment of Coronary Microvascular

  3. Caladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate Update

    BASKING RIDGE, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

  4. Caladrius Biosciences to Host 2019 Third Quarter Financial Results and Business Update Conference Call on Wednesday, November 6, 2019 at 4:30 p.m. Eastern Time

    BASKING RIDGE, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

  5. Caladrius Biosciences to Participate at the Upcoming October Conferences

    BASKING RIDGE, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data did not meet primary endpoint - February 13, 2019.
CLBS03 (The Sanford Project T-Rex Study)
Type 1 diabetes
Announced January 2016 that Phase 3 trial has been discontinued
CLBS20
Metastatic melanoma
Phase 2 full data due early 2020.
CLBS16 (CLBS14-CMD) - ESCaPE-CMD
Coronary microvascular dysfunction (CMD)
Phase 3 trial will not be initiated until funding determined.
CLBS14-NORDA
Angina
Phase 2 data due late-2020 or early 2021.
CLBS12
Critical Limb Ischemia (CLI)

Latest News

  1. Caladrius Biosciences to Participate at Upcoming December Conferences

    BASKING RIDGE, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

  2. Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019

    Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events CLBS16 cell therapy shows promise as a significant advancement in treatment of Coronary Microvascular

  3. Caladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate Update

    BASKING RIDGE, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

  4. Caladrius Biosciences to Host 2019 Third Quarter Financial Results and Business Update Conference Call on Wednesday, November 6, 2019 at 4:30 p.m. Eastern Time

    BASKING RIDGE, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

  5. Caladrius Biosciences to Participate at the Upcoming October Conferences

    BASKING RIDGE, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

  6. Caladrius Biosciences to Participate at the Upcoming September Conferences

    BASKING RIDGE, N.J., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements